In recent years, GLP-1 receptor agonist drugs have become one of the most widely discussed therapies for the treatment of obesity and type 2 diabetes. Molecules such as semaglutide and tirzepatide have changed clinical expectations, especially in pathways linked to weight loss and glycaemic control.

The therapeutic picture, however, requires attention. Alongside the benefits, there is a growing need to better understand less frequent side effects. These include acute pancreatitis, a possible inflammation of the pancreas that can present with intense abdominal pain. In some cases, the pain is accompanied by persistent nausea or vomiting.

So let us take stock of the situation and see what is known about GLP-1 drugs and pancreatitis.

GLP-1 drugs and pancreatitis: is there really a risk?

Acute pancreatitis is among the possible adverse events associated with GLP-1 drugs and dual GLP-1/GIP drugs. Regulatory authorities invite doctors and patients to recognise immediately the signs compatible with this condition. In suspected cases, in fact, therapy must be stopped immediately. Naturally, if the diagnosis is confirmed, the drug can no longer be prescribed to the patient. 1 2

In particular, attention should be paid if severe and persistent abdominal pain occurs, which sometimes radiates to the back, and may be accompanied by vomiting. We should remember that nausea or a feeling of fullness are among the side effects of Ozempic and other GLP-1 drugs, especially in the early stages of treatment or after a dosage increase. In the case of pancreatitis, however, the pain has a very high intensity.

The scientific evidence remains heterogeneous. The EMA review of GLP-1-based therapies did not confirm an increased risk of pancreatic events with the data available at the time.3 The CHMP, in simple terms, concluded that the available data did not confirm an increased risk of pancreatic adverse events, while recognising uncertainties about long-term pancreatic effects. Pharmacovigilance analyses, however, continue to report observed cases and, as a result, keep the issue open.4 For this reason, it becomes essential to assess, case by case, the individual level of risk, especially in patients who have a clinical history of pancreatitis or gallstones.

The widespread use of these drugs makes it even more important to avoid shortcuts: if treatment moves outside the boundaries of rigorous medical assessment, the risks and misuse of weight-loss medications inevitably increase.

How GLP-1 drugs act on the pancreas

To understand the relationship between GLP-1 and pancreatitis, we need to start with the role of the pancreas in metabolism. GLP-1 receptor agonist drugs stimulate pancreatic beta cells to release insulin when blood glucose rises. They also reduce the secretion of glucagon, the hormone that promotes the release of glucose into the blood.3 This mechanism of action of GLP-1 receptor agonists explains why they are excellent drugs for the management of type 2 diabetes. In practice, the drug strengthens a response already present in the body and makes it more stable over time.

But the pancreas also performs another function because it produces various digestive enzymes, such as amylase and lipase. In some patients treated with GLP-1 drugs, these enzymes can increase disproportionately, often without symptoms. An altered value, taken on its own, however, does not tell us much. It becomes clinically relevant when it is associated with persistent pain and a symptomatic picture compatible with pancreatic inflammation.

Risk factors and patient categories to be assessed carefully

Before starting therapy with GLP-1 drugs, the doctor therefore needs to be informed about the patient’s clinical history. An episode of pancreatitis requires an in-depth assessment, even if it is not an absolute contraindication. Regulatory authorities, in fact, indicate that these drugs should be used with care in patients with a history of pancreatitis.1

Another element to assess is gallbladder health. Gallstones and biliary sludge can favour obstruction of the bile ducts and increase the risk of pancreatic inflammation. A meta-analysis published in JAMA Internal Medicine observed an increased risk of gallbladder and biliary tract diseases in patients treated with GLP-1 agonists, with a stronger association in weight-loss trials.5

The speed of weight loss should not be underestimated either. During very rapid weight loss, bile may become richer in cholesterol and the gallbladder may empty less regularly. In such a situation, biliary sludge or gallstones may form, representing one of the most relevant risks for biliary pancreatitis.6

To sum up, we can say that the factors to be assessed with greater attention are:

  • previous pancreatitis, especially if recent or recurrent;
  • gallstones or previous gallbladder problems;
  • very high triglycerides, because they can favour pancreatitis;
  • high alcohol consumption, which exposes the pancreas to additional stress;
  • very rapid weight loss, especially if associated with a marked reduction in food intake;
  • switching between GLP-1 drugs, when the change takes place without cautious titration.

The initial assessment therefore serves to build a safer therapy. In this way, for patients with risk factors, the doctor may choose, for example, a slower titration of the therapy or closer follow-up.

Symptoms and signs not to underestimate during GLP-1 therapy

As we have anticipated, during therapy with GLP-1 drugs, many patients may experience various gastrointestinal disorders. Nausea, a feeling of fullness and vomiting often appear in the first few weeks, especially when the dosage needs to be increased.

The symptom that, more than any other, should raise concern is severe and continuous abdominal pain. It often starts in the upper abdomen and may radiate towards the back. When this pain is associated with persistent vomiting, fever or a rapid deterioration in general condition, the suspicion of acute pancreatitis must be assessed immediately.1 2

So which are the frequent symptoms of therapy and which, instead, are the signs that require urgent assessment? We have summarised the various cases in the following table.

SymptomHow to read it during therapy
Mild nauseaIt may appear at the start or after a dose increase. It should be reported if it limits nutrition and hydration.
Persistent vomitingIt requires medical attention, especially if it causes dehydration or worsens rapidly.
Strong abdominal painIt becomes a relevant sign if it remains continuous, especially in the upper abdomen.
Pain radiating to the backIt is a sign compatible with pancreatitis and requires urgent assessment.
Fever or marked weaknessIt may indicate a systemic picture. It should be communicated to the doctor immediately.

The treating doctor will then correctly identify the situation and indicate how to proceed.

Semaglutide, liraglutide and tirzepatide: what emerges from the studies

The available studies on the main GLP-1 drugs to know give us a non-alarming picture: in clinical trials, the risk of pancreatitis with GLP-1 receptor agonists generally appears low. Pharmacovigilance analyses instead show some reports to monitor, because they collect cases observed in more heterogeneous populations than those included in trials.3 4

Semaglutide has been assessed in large clinical programmes. The product information indicates the need to observe patients for symptoms of acute pancreatitis and to stop treatment in case of suspicion.2 This should not be read as proof of a high risk, but rather indicates that safety requires surveillance consistent with the severity of the event.

Liraglutide often appears in pharmacovigilance analyses among the molecules with more marked signals. This type of data should be interpreted with caution, because spontaneous reports can be affected by many factors: number of prescriptions, media attention and characteristics of the patients treated. They remain useful, however, for guiding healthcare staff monitoring.4

Tirzepatide, a dual GLP-1/GIP agonist, has evolving data. The information provided by the FDA, in line with what has been said so far, indicates that the patient should be observed for persistent or severe abdominal pain, with possible radiation to the back, and that the drug should be stopped if pancreatitis is suspected.6 According to the available reviews, in clinical trials tirzepatide does not show relevant signs of an increased risk of pancreatitis. The health of the gallbladder and bile ducts should still be monitored, because stones or biliary sludge may contribute to pancreatic risk.7

Risk-benefit ratio and safe use of GLP-1 drugs

We can say that the risk-benefit ratio of GLP-1 drugs remains favourable when therapy is prescribed to correctly selected patients. We know, in fact, that in the case of type 2 diabetes, these are excellent molecules for improving glycaemic control and that, in the treatment of obesity, they can favour clinically relevant weight loss. Pancreatic risk should therefore be interpreted within a complete clinical assessment, one that does not reduce treatment to the mere possibility of a rare adverse event.

The doctor, therefore, will assess any previous pancreatitis, the presence of gallstones, triglyceride levels and the patient’s general condition. In the same way, they will study the most appropriate dosage titration, because too rapid an increase in dose can worsen gastrointestinal tolerability and make it more difficult to distinguish a common disorder from a clinically relevant sign.1 8

The patient, on the other hand, must know which symptoms to observe. Mild and transient abdominal pain can have many causes, while strong, continuous pain radiating to the back requires immediate contact with the doctor.

We have then seen that therapy management also requires monitoring of the quality of weight loss, as very rapid weight loss can increase the risk of biliary problems, especially in predisposed subjects.5 For this reason, the pathway should include a nutritional assessment and appropriate support for the patient’s new metabolic phase.

The work of Cor.Con. International fits precisely into this perspective of multidisciplinary support. The supplements for the metabolic system developed by the company are formulated to accompany the patient in every phase of therapy: to counteract the gastrointestinal disorders and fatigue typical of the first period, but also to protect muscle mass during treatment and prevent the rebound effect at the end of treatment. Discover all the formulations!

References

  1. Medicines and Healthcare products Regulatory Agency (MHRA), GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases, Drug Safety Update, 29 gennaio 2026. ↩︎
  2. DailyMed, National Library of Medicine, WEGOVY (semaglutide) injection, solution — Prescribing Information.  ↩︎
  3. European Medicines Agency (EMA), Investigation into GLP-1-based diabetes therapies concluded, 26 luglio 2013. ↩︎
  4. Guo H., Guo Q., Li Z., Wang Z., Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis, Frontiers in Pharmacology, 2024;15:1461398. ↩︎
  5. He L. et al., Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials, JAMA Internal Medicine, 2022;182(5):513-519. ↩︎
  6. U.S. Food and Drug Administration, MOUNJARO (tirzepatide) injection, for subcutaneous use — Prescribing Information, revisione 2025. ↩︎
  7. Zeng Q. et al., Safety issues of tirzepatide: pancreatitis and gallbladder or biliary disease, Frontiers in Endocrinology, 2023;14:1214334. ↩︎
  8. Mehta A.E., Lomeli L.D., Pantalone K.M., Glucagon-like peptide-1 receptor agonists and pancreatitis, Cleveland Clinic Journal of Medicine, 2025;92(8):483-489. ↩︎